drugset / Trial / NCT03732001
A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC
Phase 2
Unknown
80 enrolled
China Medical University, China
Affiliated Zhongshan Hospital of Dalian University · collabAnshan Tumor Hospital · collabBenxi Cental Hospital · collabGeneral Hospital of Shenyang Military Region · collabPanjin Central Hospital · collabPanjin Liaohe Oilfield Gem Flower Hospital · collabShengjing Hospital · collabShenyang Chest Hospital · collabThe First People's Hospital of Jingzhou · collabThe People's Hospital of Liaoning Province · collabThe Second Affiliated Hospital of Dalian Medical University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the efficacy and safety of Anlotinib in combination with Docetaxel versus Docetaxel in patients with advanced non-small lung cancer after failure of first-line Chemotherapy .
Timeline
- Start
- 2018-11-08
- Primary completion
- 2019-11-09
- Completion
- 2020-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |